Tzana Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 8.52%
- Profit Growth -67.64%
- Ebitda 16.66%
- Net Worth -107.44%
- Total Assets -48.23%
About Tzana Pharmaceuticals
Tzana Pharmaceuticals Private Limited (TPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 07 June 2017 (Seven years and eight months 20 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Electrnoics Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chundanveetil Najeeb, Farzana Abdul, and Abdulbijur Vallarkodath serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U52601KA2017PTC103665
- Company No.
103665
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jun 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Tzana Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chundanveetil Najeeb  | Director | 07-Jun-2017 | Current |
| Farzana Abdul | Additional Director | 12-Jan-2018 | Current |
| Abdulbijur Vallarkodath | Director | 07-Jun-2017 | Current |
Financial Performance of Tzana Pharmaceuticals.
Tzana Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 8.52% increase. The company also saw a substantial fall in profitability, with a 67.64% decrease in profit. The company's net worth observed a substantial decline by a decrease of 107.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tzana Pharmaceuticals?
Unlock access to Tzana Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Avallark Services LlpFarzana Abdul and Abdulbijur Vallarkodath are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Tzana Pharmaceuticals?
Unlock and access historical data on people associated with Tzana Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tzana Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tzana Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.